360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Neulasta

Type: Product

Name: Neulasta

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Manufacturing

OsoBio Names Quality VP

Related Searches: Pharmaceutical manufacturing • www.contractpharma.com • cGMP • •Related Breaking NewsDavid M. Lee has been appointed vice president of quality at OsoBio. Mr. Lee is responsible for overseeing all quality-related functions to ensure continued ... [Published Contract Pharma - May 09 2013]

Entities: Manufacturing, Aseptic, Neupogen, Neulasta, M Lee

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Amgen Inc

Drug firm reaches $11M settlement

New York state once again will benefit from a multimillion-dollar settlement with a drug company.Attorney General Eric Schneiderman announced that New York and 35 other states reached an $11 million settlement with Amgen Inc. The agreement resolves claims ... [Published Buffalo Law Journal - May 06 2013]

Entities: Medicaid, Amgen Inc, Drugs

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Mark Rubinstein: Medication Nation

As a physician and psychiatrist, I certainly have nothing against medications. Over the years, I've prescribed them, and have had a great deal of success when they've been used appropriately. But over the last few years, there's been a dramatic change ... [Published Huffington Post - May 03 2013]

Entities: Mark Rubinstein, Patient, Antibiotic, Bacteria

First reported May 02 2013 - Updated May 03 2013 - 1 reports

filgrastim

The FDA Is on the Verge of Approving the First Drug Treatment for Radiation Poisoning

Checking for radiation exposure, via the Air ForceOn Friday, the FDA will discuss whether it is comfortable recommending a blood-boosting drug to treat people who survive a nuclear meltdown or atomic war.The National Institutes of Health thinks it may ... [Published Motherboard Magazine - May 02 2013]

Entities: filgrastim, Radiation, Drugs

First reported May 01 2013 - Updated May 02 2013 - 5 reports

Drugs from Amgen, others assessed by FDA as radiation treatments

9:16pm BSTMay 1 (Reuters) - Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.The drugs, known ... [Published Reuters UK - May 01 2013]

Entities: Amgen Inc, Radiation, Drugs, Neupogen, treatments

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Enbrel

Amgen, Inc. (AMGN): What’s Its Next Catalyst?

Amgen, Inc. (NASDAQ: AMGN ) stock has been on a bit of a roller coaster lately. Shares are up 23% year to date, but 8% off the high set earlier this month before the company reported first-quarter earnings.It wasn’t prettyAdjusted earnings per share was ... [Published InsiderMonkey.com - May 02 2013]

Entities: Amgen Inc, Catalyst, Enbrel, HUMIRA, Drugs

First reported May 01 2013 - Updated May 01 2013 - 2 reports

Alcoa Inc

Evening Business News briefing

_ J.C. Penney apologizes to customersJ.C. Penney is sorry and it wants your business back. Thats the gist of its latest ad, a public mea culpa which the mid-priced department-store put on its YouTube and Facebook pages. The ad, titled Its no secret, shows ... [Published Delaware Online - May 01 2013]

Entities: Cermaq Asa, Alcoa Inc, Neupogen, Casino, T-Mobile International AG & Co

First reported Apr 30 2013 - Updated May 01 2013 - 4 reports

New York to get $3.3M from drug maker

By: John Golden Posted date: May 01, 2013 In: Government, Health Care, Law, Westchester | comment : 0Drug manufacturer Amgen Inc. will pay $11 million to settle claims by New York and 35 other states that the company’s inflated pricing data led to overpayments ... [Published Fairfield Business Journal - May 01 2013]

Entities: Amgen Inc, Drugs, Medicaid

First reported Apr 29 2013 - Updated Apr 30 2013 - 3 reports

Attorney General Bondi and 35 Other Attorneys General Reach Nearly $11 Million Settlement with Amgen, Inc. Over False Claims

TALLAHASSEE, Fla.-Attorney General Pam Bondi today announced that Florida, along with 35 other attorneys general, have reached a nearly $11 million settlement with Amgen, Inc. resolving false claims allegations. Allegedly, Amgen violated state false claims ... [Published Noodls - Apr 30 2013]

Entities: Amgen Inc, Pam Bondi, Medicaid, Attorney General, Drugs

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

HANMI PHARMACEUTICAL CO. LTD. : Spectrum Pharm. Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate

Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced NeutropeniaIn U.S.-based Phase 1 trial, SPI-2012 demonstrated increase of neutrophil count similar to Neulasta(R) ... [Published 4 Traders - Apr 18 2013]

Entities: Hanmi Pharmaceutical, neutropenia, Phase II

First reported Jan 28 2013 - Updated Jan 28 2013 - 1 reports

Amgen's phase III PAVES study evaluating Neulasta in patients with colorectal cancer meets primary endpoint

Amgen, a multinational biopharmaceutical company discovers, develops, manufactures and delivers innovative human therapeutics, has reported results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a phase III trial which evaluated Neulasta (pegfilgrastim) ... [Published PharmaBiz - Jan 28 2013]

Entities: Neulasta, primary endpoint, FOLFOX, Colorectal Cancer

First reported Jan 27 2013 - Updated Jan 27 2013 - 1 reports

Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta pegfilgrastim In ...

Study Shows Neulasta Reduced the Incidence of Febrile Neutropenia in Patients With Colorectal Cancer Receiving FOLFOX or FOLFIRI and Bevacizumab ... [Published BioPortfolio - Jan 27 2013]

Entities: Neulasta, pegfilgrastim, Amgen Inc, Phase III

Quotes

...advancing two key clinical programs for Nektar over the past quarter," said Howard W Robin, President and Chief Executive Officer of Nektar. "Our partner Bayer initiated Phase 3 studies for Amikacin Inhale in gram-negative pneumonia.$ Up to 90% of hospital pneumonias occur in patients who are on ventilators and Amikacin Inhale could provide physicians with a new treatment option for treating these deadly pneumonias.$ $ In addition, Nektar initiated our second Phase 2 study for NKTR-181, our wholly-owned analgesic molecule which has received Fast Track Status from the FDA.$ We expect to report data from both Phase 2 studies of NKTR-181 during the summer."

Nektar Therapeutics Reports Financial Results for the First Quarter of 2013 PR Newswire [Published Yahoo! Finance - May 09 2013]

...Date: June 20, 2013, 7:30 a.m. 9:30 a.m. Pacific Time Poster 1598130: "Opioids With Lower Brain Uptake Are Less Recognizable in Rat Drug Discrimination Tests and thus Potentially Less Subject to Abuse" , Harrison, S , et al. Date: June 19, 2013, 12:00 p.m. 2:00 p.m. Pacific Time Conference Call to Discuss First Quarter 2013 Financial Results

Nektar Therapeutics Reports Financial Results for the First Quarter of 2013 [Published TickerTech.com - May 09 2013]

"There are no excuses for ripping off New York state taxpayers and defrauding our Medicaid programs," Schneiderman said. "At a time when state budgets are already strained, I am committed to going after any company that rips off our taxpayers, no matter how big they are."

Drug firm reaches $11M settlement [Published Buffalo Law Journal - May 06 2013]

"This is a negative quarter," Judson Clark, an analyst with Edward Jones & Co., told Bloomberg News. "The bigger question mark is their sales numbers. It was a pretty broad-based disappointment."

Amgen aims to restock its medicine cabinet [Published Los Angeles Times - May 06 2013]

More Content

sort by: Date \| Relevance
Royalty Pharma Discloses Acceptance Levels of O... [Published Street Insider - 10 hours ago]
Amgen: Financial Analysis And Valuation [Published Seeking Alpha - 13 hours ago]
Offer Update [Published TrustNet - 14 hours ago]
Amgen Stock Checkup for May [Published Motley Fool - May 23 2013]
Royalty Pharma Increases Offer for Elan to $12.... [Published Scottrade - May 20 2013]
Royalty Pharma Increases Offer for Elan to $12.... [Published FinanzNachrichten.de - May 20 2013]
Nektar Therapeutics' President and CEO, Howard ... [Published ADVFN India - May 16 2013]
Amgen Chased By The Bubble [Published Investopedia - May 11 2013]
Amgen forms joint venture in China to boost Vec... [Published PMLive - May 10 2013]
OsoBio Appoints David M. Lee Vice President of ... [Published PR.com Press Releases - May 10 2013]
Nektar Therapeutics Reports Financial Results f... [Published Yahoo! Finance - May 09 2013]
Nektar Therapeutics Reports Financial Results f... [Published TickerTech.com - May 09 2013]
OsoBio Names Quality VP [Published Contract Pharma - May 09 2013]
OsoBio appoints David M. Lee vice president of ... [Published Prlog - May 08 2013]
Drug firm reaches $11M settlement [Published Buffalo Law Journal - May 06 2013]
Amgen aims to restock its medicine cabinet [Published Los Angeles Times - May 06 2013]
Mark Rubinstein: Medication Nation [Published Huffington Post - May 03 2013]
Drug Manufacturer Amgen Agrees To Pay Medicaid ... [Published Equities.com - May 03 2013]
Nektar to Announce Financial Results for the Fi... [Published Equities.com - May 02 2013]
Nektar to Announce Financial Results for the Fi... [Published ADVFN India - May 02 2013]
The FDA Is on the Verge of Approving the First ... [Published Motherboard Magazine - May 02 2013]
Amgen CEOs Prosper Despite (or Because of) Cont... [Published Health Care Renewal - May 02 2013]
Amgen, Inc. (AMGN): What’s Its Next Catalyst? [Published InsiderMonkey.com - May 02 2013]
Business Briefs: Teva; Vertex; CSL Behring; Boe... [Published Medical Marketing And Media - May 02 2013]
Evening Business News briefing [Published Delaware Online - May 01 2013]
Drugs from Amgen, others assessed by FDA as rad... [Published Reuters UK - May 01 2013]
New York to get $3.3M from drug maker [Published Fairfield Business Journal - May 01 2013]
FDA May Approve Drugs to Counteract Nuclear Rad... [Published Gizmodo - May 01 2013]
Midday Business News briefing [Published Delaware Online - May 01 2013]
Amgen Drugs May Boost Survival After a Nuclear ... [Published Washington Post - May 01 2013]

Blogs

sort by: Date \| Relevance
Amgen CEOs Prosper Despite (or Because of) Cont... [Published Health Care Renewal - May 02 2013] This is becoming a familiar narrative on Health Care Renewal : top health care leaders continue to enrich themselves while their organizations' behavior continues to raise ethical questions.For our latest example we return to the ongoing adventures of ...
Eight of Top 20 Drugs in Sales are Biologics [Published The Big Red Biotech Blog - Mar 18 2013] This from The Cell Culture Dish (via GEN) shows the Top 8 biologic drugs in 2012. They ranged from $4.0 B to $9.26 B, and all grew in sales in 2012. The stats appear below: Humira $9.26 B AbbVie Remicade $8.22 B Janssen & Merck Enbrel $7.96 B Amgen & ...
Drugs.com: Abilify Edges out Nexium in Sales [Published Medad Blog - Feb 20 2013] By Mia Burns Clinical drug resource Drugs.com has released its fourth quarter 2012 U.S. prescription sales data for the top 100 drugs, and Otsuka’s antipsychotic Abilify overtook AstraZeneca’s acid reducer Nexium, moving into the No. 1 spot with more ...
Drug Costs In Hospitals & Clinics To Rise 4 Per... [Published Pharmalot - Feb 19 2013] The cost of medications administered by clinics and hospitals are expected to rise by as much as 4 percent this year, which is less than in previous years, thanks to the increasing availabitily of lower-cost generics, according to a study in the American ...
Amgen Phase 3 pegfilgrastim and anti-VEGF evalu... [Published PBR - News - Jan 28 2013] Amgen Phase 3 pegfilgrastim and anti-VEGF evaluation study (PAVES) of Neulasta (pegfilgrastim) conducted in colorectal cancer patients has met its primary endpoint. ...

Press Releases

sort by: Date \| Relevance
OsoBio Appoints David M. Lee Vice President of ... [Published PR.com Press Releases - May 10 2013]
Fitch Affirms Amgen's IDR at 'BBB'; Ratings Out... [Published Business Wire - Apr 19 2013]
Amgen Announces Results From Phase 3 PAVES Stud... [Published PR Newswire: General Business - Jan 26 2013]